COGNOPTIX
Cognoptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer's Disease. Cognoptix's goal is to provide clinicians with a quick, predictive, reliable, inexpensive, and widely available test, enabling early diagnosis and treatment. The company was founded in 2001 and headquartered in Marlborough, Massachusetts.
COGNOPTIX
Industry:
Biotechnology Health Care Health Diagnostics Medical Device Therapeutics
Founded:
2001-01-01
Address:
Marlborough, Massachusetts, United States
Country:
United States
Website Url:
http://www.cognoptix.com
Total Employee:
1+
Status:
Active
Contact:
508-251-1546
Email Addresses:
[email protected]
Total Funding:
46.35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
BioShai
BioShai is a simple blood test for the early diagnosis of Parkinson's disease.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
NeuroQuest
Developing biomarkers for early diagnosis of Alzheimer’s disease
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
LaunchPad Venture
LaunchPad Venture investment in Venture Round - Cognoptix
Sidecar Fund2
Sidecar Fund2 investment in Venture Round - Cognoptix
New York Angels
New York Angels investment in Venture Round - Cognoptix
Harvard Business School Alumni Angels of Greater NY
Harvard Business School Alumni Angels of Greater NY investment in Venture Round - Cognoptix
Nobska Point Capital
Nobska Point Capital investment in Venture Round - Cognoptix
Alopexx Enterprises
Alopexx Enterprises investment in Venture Round - Cognoptix
LaunchPad Venture
LaunchPad Venture investment in Series D - Cognoptix
Inventages Venture Capital Investment Inc.
Inventages Venture Capital Investment Inc. investment in Series D - Cognoptix
Alopexx Enterprises
Alopexx Enterprises investment in Series D - Cognoptix
Maine Angels
Maine Angels investment in Debt Financing - Cognoptix
Official Site Inspections
http://www.cognoptix.com Semrush global rank: 8.2 M Semrush visits lastest month: 353
- Host name: box2120.bluehost.com
- IP address: 70.40.216.90
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Cognoptix"
Cognoptix: A Leader in Non-Invasive Alzheimer’s …
Mar 22, 2021 Cognoptix is developing a simple, non-invasive beta amyloid eye scanning test for use in adult patients being evaluated for Alzheimer’s DiseaseSee details»
Cognoptix - Crunchbase Company Profile & Funding
Cognoptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer's Disease. Cognoptix's goal is to …See details»
About Cognoptix
Cognoptix’ goal is to provide clinicians with a highly accurate, reliable, inexpensive, convenient and widely available test that can be performed quickly on-site in the comfort of a physician’s office, to enable swift intervention and …See details»
Cognoptix 2025 Company Profile: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for Cognoptix. Use the PitchBook Platform to explore the full profile.See details»
Cognoptix - LinkedIn
Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker ...See details»
Cognoptix - Funding, Financials, Valuation & Investors
Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.See details»
Cognoptix - Products, Competitors, Financials, Employees, …
Cognoptix Frequently Asked Questions (FAQ) When was Cognoptix founded? Cognoptix was founded in 2019. Where is Cognoptix's headquarters? Cognoptix's headquarters is located at …See details»
Cognoptix - VentureRadar
Cognoptix's goal is to provide clinicians with a predictive, reliable, inexpensive and widely available test that can be performed quickly and accurately by a general practitioner in an …See details»
Technology - Cognoptix
Cognoptix’ SAPPHIRE platform is a compact, easy to use, clinical device for in situ patient examination in the comfort of a doctor’s office. The combined platform is currently available in the United States for investigational use only and is …See details»
Neuroptix Corporation - VentureRadar
Cognoptix USA Private Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device …See details»
Cognoptix Announces New Scientific Advisory Board with …
Nov 19, 2020 Cognoptix, a leading diagnostics company dedicated to early detection of Alzheimer’s disease (AD), announced today the formation of its new Scientific Advisory Board …See details»
COGNOPTIX: EYE SCANNING TEST FOR EARLY DETECTION OF …
Jan 3, 2013 Cognoptix was founded on the basis of a new and promising biomarker for the detection of beta amyloid proteins responsible for the formation of plaques in the brains of …See details»
News - Cognoptix
COMPANY NEWS Cognoptix Investor PresentationDecember 2021 Read Now “Cognoptix: Pioneering the Early Detection of Alzheimer’s Disease”Cognoptix was recently profiled by …See details»
Cognoptix, Inc. | BBB Business Profile | Better Business Bureau
Cognoptix, Inc. is NOT a BBB Accredited Business. To become accredited, a business must agree to BBB Standards for Trust and pass BBB's vetting process.See details»
Cognoptix Announces Formation of a New Board of Directors
Dec 30, 2020 Cognoptix Announces Formation of a New Board of Directors MARLBOROUGH, Mass. , Dec. 30, 2020 — Cognoptix is a breakthrough diagnostics company developing an …See details»
Cognoptix Announces Formation of a New Board of Directors
Dec 30, 2020 Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another …See details»
Alzheimer's & Dementia - Alzheimer’s Association
Jul 1, 2019 Cognoptix has developed a b-amyloid specific office-based eye test, Sapphire II, with demonstrated ability to distinguish between normal subjects and subjects with probable AD …See details»
A Simple Eye Scan - cognoptix.com
Dec 17, 2021 Cognoptix’s immediate next step is to expand its sample size by added 5 cognitively normal and 5 new AD patients Results of 2000 simulations predict that adding …See details»
Eye Test for Alzheimer's: Cognoptix Promises Cheaper, Faster, Better
Apr 6, 2014 VIDEO+ARTICLE Cognoptix announced strong results in a clinical trial of its SAPPHIRE II eye test. It successfully identified Alzheimer’s via the human eye’s beta-amyloid …See details»
Discover Cognoptix - Cognoptix
Subscribe to our company news email list and receive Cognoptix news as it is released. To protect your privacy, your email address will be used only for this news distribution list.See details»